These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 24234513)

  • 1. Novel oral anticoagulants for stroke prevention in the geriatric population.
    Kim D; Barna R; Bridgeman MB; Brunetti L
    Am J Cardiovasc Drugs; 2014 Feb; 14(1):15-29. PubMed ID: 24234513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Personalizing oral anticoagulant treatment in patients with atrial fibrillation.
    Capranzano P; Miccichè E; D'Urso L; Privitera F; Tamburino C
    Expert Rev Cardiovasc Ther; 2013 Aug; 11(8):959-73. PubMed ID: 23957907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Practical considerations in the use of novel oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation.
    Deitelzweig S
    Cardiovasc Ther; 2014 Apr; 32(2):74-81. PubMed ID: 24119252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of oral anticoagulants in patients with atrial fibrillation.
    Greenspon AJ
    Postgrad Med; 2012 Nov; 124(6):7-16. PubMed ID: 23322134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New oral anticoagulants in practice: pharmacological and practical considerations.
    Wang Y; Bajorek B
    Am J Cardiovasc Drugs; 2014 Jun; 14(3):175-89. PubMed ID: 24452600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel oral anticoagulants for stroke prevention in atrial fibrillation: results of the European Heart Rhythm Association survey.
    Lip GY; Bongiorni MG; Dobreanu D; Lewalter T; Hastrup Svendsen J; Blomström-Lundqvist C;
    Europace; 2013 Oct; 15(10):1526-32. PubMed ID: 24072770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban.
    Gong IY; Kim RB
    Can J Cardiol; 2013 Jul; 29(7 Suppl):S24-33. PubMed ID: 23790595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel oral anticoagulants in non-valvular atrial fibrillation.
    Potpara TS; Lip GY
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):115-29. PubMed ID: 23953900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New anticoagulants (dabigatran, apixaban, rivaroxaban) for stroke prevention in atrial fibrillation.
    Aguilar MI; Kuo RS; Freeman WD
    Neurol Clin; 2013 Aug; 31(3):659-75. PubMed ID: 23896498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
    Lip GY; Larsen TB; Skjøth F; Rasmussen LH
    J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beyond warfarin: a patient-centered approach to selecting novel oral anticoagulants for stroke prevention in atrial fibrillation.
    Patel KK; Mehdirad AA; Lim MJ; Ferreira SW; Mikolajczak PC; Stolker JM
    J Hosp Med; 2014 Jun; 9(6):400-6. PubMed ID: 24715600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Consideration of clinical variables for choosing new anticoagulant alternatives to warfarin for the management of non-valvular atrial fibrillation.
    Lu Y; Branstad R; Karim RM; Asinger RW
    J Clin Pharm Ther; 2014 Dec; 39(6):628-36. PubMed ID: 25252149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: dawn of a new era.
    Contractor T; Levin V; Martinez MW; Marchlinski FE
    Postgrad Med; 2013 Jan; 125(1):34-44. PubMed ID: 23391669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of Non-Vitamin K Antagonist Oral Anticoagulants in Special Patient Populations with Nonvalvular Atrial Fibrillation: A Review of the Literature and Application to Clinical Practice.
    Kalabalik J; Rattinger GB; Sullivan J; Slugocki M; Carbone A; Rivkin A
    Drugs; 2015 Jun; 75(9):979-98. PubMed ID: 25998374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unanswered questions and research priorities to optimise stroke prevention in atrial fibrillation with the new oral anticoagulants.
    Hankey GJ
    Thromb Haemost; 2014 May; 111(5):808-16. PubMed ID: 24285341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel anticoagulants for non-valvular atrial fibrillation.
    Xu B; Whitbourn R
    Heart Lung Circ; 2012 Aug; 21(8):463-7. PubMed ID: 22542860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Which oral anticoagulant for which atrial fibrillation patient: recent clinical trials and evidence-based choices.
    Cairns JA
    Can J Cardiol; 2013 Oct; 29(10):1165-72. PubMed ID: 23932012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Target-specific oral anticoagulants for stroke prevention in patients with atrial fibrillation: real-world considerations.
    Rosenberg DJ; Ansell J
    Hosp Pract (1995); 2012 Aug; 40(3):50-7. PubMed ID: 23086094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stroke prevention in atrial fibrillation patients with chronic kidney disease.
    Hart RG; Eikelboom JW; Brimble KS; McMurtry MS; Ingram AJ
    Can J Cardiol; 2013 Jul; 29(7 Suppl):S71-8. PubMed ID: 23790601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.